強
強気
強気 · 25%PYPD
$4.99
シナリオ価格
$5.670
-0.146 (-2.58%)終値時点
Loading chart…
- 高値
- 5.930
- 始値
- 5.820
- 出来高加重平均価格
- 5.65
- 出来高
- 242.04K
- 時価総額
- 20.15M
- 安値
- 5.360
- 売買代金
- 1.37M
- EV/EBITDA（TTM）
- 0.00
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
AI分析 of PolyPid Ltd (PYPD)
買いPolyPid Ltd is a good buy right now, with a current price of $5.42 and a strong analyst price target of $10 from Oppenheimer, indicating a potential upside of 84%. The company has received FDA priority review for its product D-PLEX100, which could significantly enhance its market position and revenue streams. Additionally, the stock has shown a year-to-date change of +24.60%, reflecting positive momentum. However, the main risk is the ongoing net losses, with a reported loss of $7.8 million in Q2 2026, which investors should monitor closely.
バリュエーション指標
PolyPid Ltd（PYPD）の現在の予想PERは0.00で、5年平均は-1.47です。
Alphio AI による PYPD の価格シナリオ
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。
イベントタイムライン
ニュース
6.010-27CNBCMajor Wall Street Rating Updates
8.510-15NewsfilterPolyPid Unveils 'PolyPid 2030' Long-Term Strategy
9.508-19NASDAQ.COMPolyPid Reports Q2 Loss Reduction Amid Strategic Partnerships
9.007-29seekingalphaPolyPid Receives FDA Priority Review for D-PLEX100
9.007-29NASDAQ.COMPolyPid's D-PLEX100 Receives FDA Priority Review
PYPD のよくある質問 — Alphio AI が回答
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).
PolyPid Ltd is a good buy right now, with a current price of $5.42 and a strong analyst price target of $10 from Oppenheimer, indicating a potential upside of 84%. The company has received FDA priority review for its product D-PLEX100, which could significantly enhance its market position and revenue streams. Additionally, the stock has shown a year-to-date change of +24.60%, reflecting positive momentum. However, the main risk is the ongoing net losses, with a reported loss of $7.8 million in Q2 2026, which investors should monitor closely.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加関連記事
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。